Dr. Ford has a unique background. He has over forty years of experience in the health care field. He has spent his entire career in the pharmaceutical industry. He started out after an NIH post-doctoral fellowship at Stanford University, as a medicinal chemist at CIBA Pharmaceuticals Inc in Summit NJ. Where he synthesized novel compounds in his own laboratory. In this laboratory he completed one of the first syntheses of prostaglandin E1 (Alprostadil®), for which he was awarded a D.Sc. degree. He subsequently became responsible for all Medicinal Chemistry in the US for the successor company CIBA-Geigy. He then became Executive Director reporting to the VP for R&D in the US. In this capacity he was also responsible for Drug Metabolism, Bioanalytical Research, and a Chemical Development operation which provided material for the IND toxicology studies and Phase I studies in man.
Dr. Ford left CIBA-Geigy in 1981 to enter Washington University School of Medicine in St Louis. He obtained an MD degree in 1985 and trained in internal medicine at Jewish Hospital in St. Louis. He boarded in Internal Medicine and Clinical Pharmacology. He joined the Clinical Pharmacology department at Squibb in 1988, as Associate Director. He subsequently became Executive Director of Clinical Pharmacology in the successor company Bristol-Myers Squibb, and was responsible for the early clinical development plans for the Cardiovascular, Metabolic, Dermatological, Urological and Neuroscience programs. He played an active role in the interfaces with Regulatory Affairs and Clinical Research.
Dr. Ford is a Fellow of the American College of Physicians and the American College of Clinical Pharmacology. He is on the Editorial Board of the Journal of Clinical Pharmacology. He is Clinical Associate Professor of Medicine at the Robert Wood Johnson School of Medicine, UMDNJ, New Brunswick, NJ. In 2005 he received the volunteer Faculty Teaching Award from the Department of Medicine.